Synthesis and structure-activity relationships of phenoxypyridine derivatives as novel inhibitors of the sodium-calcium exchanger

Bioorganic and Medicinal Chemistry

Volumn 12, Issue 19, 2004, Pages 5039-5056

  Kuramochi, Takahiro ^a   Kakefuda, Akio ^a   Yamada, Hiroyoshi ^a   Sato, Ippei ^a   Taguchi, Taku ^a   Sakamoto, Shuichi ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Anti arrhythmias; NCX; Sodium calcium exchanger; transporter

Indexed keywords

2 [2 [4 (4 NITROBENZYLOXY)PHENYL]ETHYL]ISOTHIOUREA METHANESULFONATE; 2 PYRROLIDIN 1 YL N [6 [4 (2 THIENYLMETHOXY)PHENOXY]PYRIDIN 3 YL]ACETAMIDE; 2 PYRROLIDIN 1 YL N [6 [4 (3 THIENYLMETHOXY)PHENOXY]PYRIDIN 3 YL]ACETAMIDE; 3 FLUORO N [4 [[5 [(PYRROLIDIN 1 YLACETYL)AMINO]PYRIDIN 2 YL]OXY]PHENYL]BENZAMIDE; 3 FLUORO N METHYL N [4 [[5 [(PYRROLIDIN 1 YLACETYL)AMINO]PYRIDIN 2 YL]OXY]PHENYL]BENZAMIDE; CARDIOVASCULAR AGENT; N (3 FLUOROPHENYL) 4 [[5 [(PYRROLIDIN 1 YLACETYL)AMINO]PYRIDIN 2 YL]OXY]BENZAMIDE; N (3 FLUOROPHENYL) N METHYL 4 [[5 [(PYRROLIDIN 1 YLACETYL)AMINO]PYRIDIN 2 YL]OXY]BENZAMIDE; N [6 (4 METHOXYPHENOXY)PYRIDIN 3 YL] 2 PYRROLIDIN 1 YLACETAMINE; N [6 [2 CHLORO 4 [(3 FLUOROBENZYL)OXY]PHENOXY]PYRIDIN 3 YL] 2 PYRROLIDIN 1 YLACETAMIDE OXALATE; N [6 [3 [(3 FLUOROBENZYL)OXY]PHENOXY]PYRIDIN 3 YL] 2 PYRROLIDIN 1 YLACETAMIDE; N [6 [3 CHLORO 4 [(3 FLUOROBENZYL)OXY]PHENOXY]PYRIDIN 3 YL] 2 PYRROLIDIN 1 YLACETAMIDE OXALATE; N [6 [4 (CYCLOHEXYLMETHOXY)PHENOXY]PYRIDIN 3 YL] 2 PYRROLIDIN 1 YLACETAMINE; N [6 [4 (PYRIDIN 2 YLMETHOXY)PHENOXY]PYRIDIN 3 YL] 2 PYRROLIDIN 1 YLACETAMIDE; N [6 [4 (PYRIDIN 3 YLMETHOXY)PHENOXY]PYRIDIN 3 YL] 2 PYRROLIDIN 1 YLACETAMIDE; N [6 [4 (PYRIDIN 4 YLMETHOXY)PHENOXY]PYRIDIN 3 YL] 2 PYRROLIDIN 1 YLACETAMIDE; N [6 [4 [(3 FLUOROBENZYL)(METHYL)AMINO]PHENOXY]PYRIDIN 3 YL] 2 PYRROLIDIN 1 YLACETAMIDE OXALATE; N [6 [4 [(3 FLUOROBENZYL)OXY] 2 METHOXYPHENOXY]PYRIDIN 3 YL] 2 PYRROLIDIN 1 YLACETAMIDE OXALATE; N [6 [4 [(3 FLUOROBENZYL)OXY] 3 METHOXYPHENOXY]PYRIDIN 3 YL] 2 PYRROLIDIN 1 YLACETAMIDE OXALATE; N [6 [4 [(3 FLUOROBENZYL)OXY] 3 METHYLPHENOXY]PYRIDIN 3 YL] 2 PYRROLIDIN 1 YLACETAMIDE OXALATE; N [6 [4 [(3 FLUOROBENZYL)OXY]PHENOXY]PYRIDIN 3 YL] 2 PYRROLIDIN 1 YLPROPANAMIDE OXALATE; N [6 [4 [(3 FLUOROBENZYL)OXY]PHENOXY]PYRIDIN 3 YL] N METHYL 2 PYRROLIDIN 1 YLACETAMIDE OXALATE; N [6 [4 [(3 FLUOROPHENOXY)METHYL]PHENOXY]PYRIDIN 3 YL] 2 PYRROLIDIN 1 YLACETAMINE; N [6 [4 [2 (3 FLUOROPHENYL)ETHOXY]PHENOXY]PYRIDIN 3 YL] 2 PYRROLIDIN 1 YLACETAMINE OXALATE; N [6 [4 [2 (3 FLUOROPHENYL)ETHYL]PHENOXY]PYRIDIN 3 YL] 2 PYRROLIDIN 1 YLACETAMIDE; N [6 [4 [2 (3 FLUOROPHENYL)VINYL]PHENOXY]PYRIDIN 3 YL] 2 PYRROLIDIN 1 YLACETAMINE; PROTEIN INHIBITOR; PYRIDINE DERIVATIVE; SODIUM CALCIUM EXCHANGE PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL CELL; ARTICLE; CELL LINE; DRUG ACTIVITY; DRUG DESIGN; DRUG SYNTHESIS; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ANIMALS; CALCIUM; CELL LINE; CRICETINAE; FIBROBLASTS; INHIBITORY CONCENTRATION 50; NECROSIS; PYRIDINES; SODIUM-CALCIUM EXCHANGER; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 4444293996     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2004.07.038     Document Type: Article

References (20)

1. L. Ver Donck, B. Marcal, and F. Verdonck Cardiovasc. Res. 27 1993 349
2. D.G. Allen, S.P. Cairns, S.E. Turvey, and J.A. Lee Adv. Exp. Med. Biol. 346 1993 19
3. W. Scholz, U. Albus, H.J. Lang, W. Linz, P.A. Martorana, H.C. Englert, and B.A. Scholkens Br. J. Pharmacol. 109 1993 562
4. T. Kawada, Y. Yoshida, H. Sakurai, and S. Imai Jpn. J. Pharmacol. 59 1992 191
5. S.C. Dennis, W.A. Coetzee, E.J. Cragoe Jr., and L.H. Opie Circ. Res. 66 1990 1156
6. M.C. Haigney, H. Miyata, E.G. Lakatta, M.G. Stern, and H.S. Silverman Circ. Res. 71 1992 547
7. M. Tani, and J.R. Neely Circ. Res. 65 1989 1045
8. G.J. Kaczorowski, M.L. Garcia, R. King, and R.S. Slaughter Sodium-Calcium Exchanger 1989 Oxford University Press Oxford pp 66-101
9. F. Rogister, D. Leackmann, P. Plasman, F.V. Eylen, M. Ghyoot, C. Maggetto, J. Liégeois, J. Géczy, A. Herchuelz, J. Delarge, and B. Masereel Eur. J. Med. Chem. 36 2001 597
10. T. Iwamoto, T. Watano, and M. Shigekawa J. Biol. Chem. 271 1996 22391 22397
11. Ohta, T.; Nakanishi, M.; Aibe, I.; Taguchi, M.; Tomisawa, K. JP patent 11092454, 1999
12. H. Hasegawa, M. Muraoka, K. Matsui, and A. Kojima Bioorg. Med. Chem. Lett. 13 2003 3471
13. T. Watano, J. Kimura, T. Morita, and H. Nakanishi Br. J. Pharmacol. 119 1996 555
14. P. Lipp, and L. Pott J. Physiol. 403 1988 355
15. T. Iwanoto, S. Wakabayashi, T. Imagawa, and M. Shigekawa Eur. J. Cell. Biol. 76 1998 228
16. A. Nakamura, K. Harada, H. Sugimoto, F. Nakajima, and N. Nishimura Nippon Yakurigaku Zasshi 111 1998 105
17. K. Yamamura, M. Tani, H. Hasegawa, and W. Gen Cardiovasc. Res. 52 2001 397
18. 11 Several patented compounds were synthesized and evaluated. Among them, compound 3 was the most potent NCX inhibitor in our assay. The structure was also interesting
19. Ohta, T.; Yoshimura, M.; Taguchi, M.; Hamano, A.; Tomisawa, K. JP patent 10218844, 1998
20. Ohta, T.; Nakanishi, M.; Aibe, I.; Taguchi, M.; Tomisawa, K. JP patent 11049752, 1999